Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 323 articles: HTML format

Single Articles

September 2026
1. FORSSTROM V, Itala-Remes M
   Allogeneic hematopoietic cell transplantation in Hodgkin lymphoma-single-center retrospective analysis.
   Leuk Lymphoma. 2026 Sep 3:1-3. doi: 10.1080/10428194.2026.2727811.
   PubMed    
   
   
   August 2026
2. IBRAHIM RAE, Ahmed BA, Bahr AR, ElShazly M, et al
   Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.
   Leuk Lymphoma. 2026 Aug 30:1-5. doi: 10.1080/10428194.2026.2725345.
   PubMed     Abstract available
   
   
   
3. TROTIER D, Liu M, Augustine A, Vembu K, et al
   Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.
   Leuk Lymphoma. 2026 Aug 16:1-9. doi: 10.1080/10428194.2026.2715204.
   PubMed     Abstract available
   
   
   
4. WANG C, Liang Y, Liu X, Zeng L, et al
   Effects of O-GlcNAc glycosylated modified transferase on prognosis of diffuse large B-cell lymphoma and analysis of downstream targets.
   Leuk Lymphoma. 2026 Aug 13:1-26. doi: 10.1080/10428194.2026.2712107.
   PubMed     Abstract available
   
   
   
5. HAVERKOS BM, Chang C, Ristuccia R, Chang Y, et al
   Treatment utilization and outcomes in patients with mycosis fungoides and Sezary syndrome receiving mogamulizumab in community and academic practice in the United States clinical practice.
   Leuk Lymphoma. 2026;67:2035-2047.
   PubMed     Abstract available
   
   
   July 2026
6. LIN Y, Palivela M, Lakzadeh P, Limbrick-Oldfield E, et al
   Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.
   Leuk Lymphoma. 2026 Jul 27:1-16. doi: 10.1080/10428194.2026.2695323.
   PubMed     Abstract available
   
   
   
7. AGHAZADA S, Goksel S, Ozturk H, Eroglu Kucukdiler AH, et al
   Baseline whole-body metabolic tumor volume as an independent prognostic marker in diffuse large B-cell lymphoma: a PET/cT-based study.
   Leuk Lymphoma. 2026 Jul 23:1-12. doi: 10.1080/10428194.2026.2701956.
   PubMed     Abstract available
   
   
   
8. MACMANUS M, Dowling M
   The role of radiotherapy in bridging to CAR T-cell therapy for high-grade B-cell lymphoma.
   Leuk Lymphoma. 2026 Jul 16:1-3. doi: 10.1080/10428194.2026.2694679.
   PubMed    
   
   
   
9. BELGHOUL M, Kuhnl A, Chevassut T, Sanderson R, et al
   The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review.
   Leuk Lymphoma. 2026 Jul 16:1-9. doi: 10.1080/10428194.2026.2685253.
   PubMed     Abstract available
   
   
   
10. OURA M, Ikeda D, Uehara A, Tabata R, et al
    Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma.
    Leuk Lymphoma. 2026 Jul 7:1-4. doi: 10.1080/10428194.2026.2697464.
    PubMed    
    
    
    June 2026
11. NAGEL S, Meyer C
    T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.
    Leuk Lymphoma. 2026 Jun 25:1-4. doi: 10.1080/10428194.2026.2692620.
    PubMed    
    
    
    
12. JAHAN RN, Hijbullah M, Nawal L, Lamisa KF, et al
    Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Jun 23:1-21. doi: 10.1080/10428194.2026.2683846.
    PubMed     Abstract available
    
    
    
13. SETH N, Deb PQ, Tam W
    KRAS-mutated clonal hematopoiesis gives rise to lineage-divergent B-lymphoblastic leukemia/lymphoma and persistent post-therapy monocytosis.
    Leuk Lymphoma. 2026 Jun 21:1-5. doi: 10.1080/10428194.2026.2689470.
    PubMed    
    
    
    
14. GONG IY, Xiao NM, Chen C, Bhella S, et al
    Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.
    Leuk Lymphoma. 2026 Jun 15:1-5. doi: 10.1080/10428194.2026.2682290.
    PubMed    
    
    
    
15. HEROLD S, Wieber C, Acker F, Liebers N, et al
    Treatment intensification does not improve outcomes beyond rituximab-based therapy in primary mediastinal B-cell lymphoma: a multicenter retrospective analysis.
    Leuk Lymphoma. 2026 Jun 10:1-10. doi: 10.1080/10428194.2026.2682281.
    PubMed     Abstract available
    
    
    
16. CHERNG HJ, DeStephano D, Gould P, Sabatino D, et al
    Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.
    Leuk Lymphoma. 2026 Jun 7:1-12. doi: 10.1080/10428194.2026.2678414.
    PubMed     Abstract available
    
    
    
17. SHAN Y, Chen X, Li D, Zhang W, et al
    Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series.
    Leuk Lymphoma. 2026 Jun 7:1-8. doi: 10.1080/10428194.2026.2656946.
    PubMed     Abstract available
    
    
    May 2026
18. LOH Z, Chung E, Wellard C, Opat S, et al
    Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.
    Leuk Lymphoma. 2026 May 26:1-9. doi: 10.1080/10428194.2026.2673099.
    PubMed     Abstract available
    
    
    
19. WOBSER M, Rosenwald A, Eisele F, Maurus K, et al
    Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2026 May 22:1-4. doi: 10.1080/10428194.2026.2672106.
    PubMed    
    
    
    
20. QU M, Ni T, Wu P
    The risk and predictors of second primary malignancies in survivors of angioimmunoblastic T-cell lymphoma: a population-based competing risk analysis.
    Leuk Lymphoma. 2026 May 22:1-13. doi: 10.1080/10428194.2026.2665246.
    PubMed     Abstract available
    
    
    
21. SAHA A, Jhaveri K, Perini GF, Chavez JC, et al
    From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.
    Leuk Lymphoma. 2026 May 19:1-13. doi: 10.1080/10428194.2026.2662494.
    PubMed     Abstract available
    
    
    April 2026
22. XIONG S, Yue N, Zhang S, Xu Y, et al
    CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma.
    Leuk Lymphoma. 2026 Apr 29:1-21. doi: 10.1080/10428194.2026.2661769.
    PubMed     Abstract available
    
    
    
23. MEZA-CAPCHA K, Boshkos M, Nieves Jimenez H, Romagnoli C, et al
    Clinicopathologic features of lymphoma-associated hemophagocytic lymphohistiocytosis in a multicenter adult cohort.
    Leuk Lymphoma. 2026 Apr 29:1-7. doi: 10.1080/10428194.2026.2663069.
    PubMed     Abstract available
    
    
    
24. THIEBLEMONT C, Caillot D, Pierre M, Branchoux S, et al
    Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).
    Leuk Lymphoma. 2026 Apr 29:1-12. doi: 10.1080/10428194.2026.2652533.
    PubMed     Abstract available
    
    
    
25. NASTOUPIL LJ, Martin Garcia-Sancho A, Izutsu K, Cartron G, et al
    Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.
    Leuk Lymphoma. 2026 Apr 28:1-13. doi: 10.1080/10428194.2026.2650672.
    PubMed     Abstract available
    
    
    
26. ALFARO E, Schelotto M, Zamaro H, Sanchez La Rosa C, et al
    Radiotherapy may be omitted in children and adolescents with classical Hodgkin lymphoma in complete remission after frontline risk and response-adapted chemotherapy: a multicenter clinical trial (LH-GALOP 2017).
    Leuk Lymphoma. 2026 Apr 28:1-8. doi: 10.1080/10428194.2026.2662496.
    PubMed     Abstract available
    
    
    
27. HU L, Lu B, Wei X, Wang Y, et al
    A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2026 Apr 24:1-8. doi: 10.1080/10428194.2026.2654977.
    PubMed     Abstract available
    
    
    
28. ZIELSKE SP, Fernandez-Valdivia R
    Molecular deconstruction of anaplastic large cell Lymphoma (ALCL).
    Leuk Lymphoma. 2026 Apr 22:1-3. doi: 10.1080/10428194.2026.2661081.
    PubMed    
    
    
    
29. MOON IJ, Choi J, Jung JM, Won CH, et al
    Clinicopathological factors associated with the prognosis and relapse of primary cutaneous marginal zone lymphoma: a retrospective cohort study.
    Leuk Lymphoma. 2026 Apr 21:1-9. doi: 10.1080/10428194.2026.2656942.
    PubMed     Abstract available
    
    
    
30. NAKAMURA D, Ueno T, Nakabeppu SI, Shyodai A, et al
    Validation of prognostic indices in adult T-cell leukemia/lymphoma and their prognostic value at the start of second-line treatment.
    Leuk Lymphoma. 2026 Apr 1:1-7. doi: 10.1080/10428194.2026.2645946.
    PubMed     Abstract available
    
    
    
31. CAMPBELL BA, Minson A, Brown RJ, Chin CK, et al
    Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2026;67:1100-1108.
    PubMed     Abstract available
    
    
    
32. TARANTINI G, Miccolis RM, Arcuti E, Buquicchio C, et al
    A new era for transplant-ineligible R/R LBCL patients: what's changing?
    Leuk Lymphoma. 2026;67:997-1004.
    PubMed     Abstract available
    
    
    
33. MADDOCKS K, Tracey M, Winfree KB, Hall Panjic E, et al
    Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.
    Leuk Lymphoma. 2026;67:1055-1065.
    PubMed     Abstract available
    
    
    
34. RALLI S, Jones SJ, Leach S, Lynch HJ, et al
    Identifying genes and pathways in familial lymphoid cancers using whole exome sequencing.
    Leuk Lymphoma. 2026;67:1014-1028.
    PubMed     Abstract available
    
    
    March 2026
35. TAKAHASHI H, Nakajima Y, Kaburaki T, Hamada T, et al
    Efficacy of CD19 CAR T-cell therapy in active vitreoretinal lymphoma.
    Leuk Lymphoma. 2026 Mar 31:1-4. doi: 10.1080/10428194.2026.2650671.
    PubMed    
    
    
    
36. JORGENSEN JB, Hansen KV, Nielsen LK, Gade IL, et al
    First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM study.
    Leuk Lymphoma. 2026 Mar 25:1-10. doi: 10.1080/10428194.2026.2642931.
    PubMed     Abstract available
    
    
    
37. KIM DH, Cha S, Koh Y, Byun JM, et al
    Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review.
    Leuk Lymphoma. 2026 Mar 22:1-10. doi: 10.1080/10428194.2026.2638438.
    PubMed     Abstract available
    
    
    
38. WALTER C, Burger MC, Siebenbrodt K, Mooshage CM, et al
    Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.
    Leuk Lymphoma. 2026 Mar 22:1-5. doi: 10.1080/10428194.2026.2647957.
    PubMed    
    
    
    
39. TRABOLSI A, Plate TE, Lavorgna T, Kronenfeld RS, et al
    Predictors and timing of venous thromboembolism and overall survival in lymphoma.
    Leuk Lymphoma. 2026 Mar 20:1-9. doi: 10.1080/10428194.2026.2644580.
    PubMed     Abstract available
    
    
    
40. SUKE SG, Wong C, Yannakou CK
    Secondary graft failure after autologous stem cell transplantation for primary central nervous system lymphoma responds to ciclosporin and eltrombopag.
    Leuk Lymphoma. 2026 Mar 19:1-3. doi: 10.1080/10428194.2026.2643746.
    PubMed    
    
    
    
41. KIM WS, Al Mansour M, Cheah C, de Holanda Farias JS, et al
    Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
    Leuk Lymphoma. 2026 Mar 17:1-11. doi: 10.1080/10428194.2026.2640453.
    PubMed     Abstract available
    
    
    
42. BAYOUMI MA, Arafah OS, Khalil EM, Kotb MH, et al
    Response-adapted de-escalation of radiotherapy in pediatric Hodgkin's lymphoma.
    Leuk Lymphoma. 2026 Mar 14:1-9. doi: 10.1080/10428194.2026.2642233.
    PubMed     Abstract available
    
    
    
43. KYVSGAARD ER, Fuglkjaer AD, Al-Mashhadi AL, Hasselbalch Riley C, et al
    A real-world comparison of CD20xCD3 bispecific antibodies versus chemotherapy regimens in 3+ line relapsed/refractory diffuse large B cell lymphoma.
    Leuk Lymphoma. 2026 Mar 11:1-5. doi: 10.1080/10428194.2026.2637858.
    PubMed    
    
    
    
44. GUOLO F, Del Sette P, Riccardi F, Ballerini F, et al
    Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.
    Leuk Lymphoma. 2026 Mar 7:1-7. doi: 10.1080/10428194.2026.2634180.
    PubMed     Abstract available
    
    
    
45. HAO X, Zhang J, Liu S, Luo L, et al
    Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.
    Leuk Lymphoma. 2026 Mar 7:1-9. doi: 10.1080/10428194.2026.2637864.
    PubMed     Abstract available
    
    
    
46. MARAGLINO AME, Sammassimo S, Clemente A, Vanazzi A, et al
    Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.
    Leuk Lymphoma. 2026 Mar 4:1-5. doi: 10.1080/10428194.2026.2639056.
    PubMed    
    
    
    
47. WENNERAS C, Alsalihi R, Karlsson V, Lewerin C, et al
    Neoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients.
    Leuk Lymphoma. 2026 Mar 4:1-8. doi: 10.1080/10428194.2026.2638447.
    PubMed     Abstract available
    
    
    
48. THIDA A, Nasirikhaneghah E, Chiu E
    Diffuse large B-cell lymphoma outcomes in an urban safety-net cohort: functional status, clinical risk, and treatment feasibility.
    Leuk Lymphoma. 2026 Mar 3:1-9. doi: 10.1080/10428194.2026.2637861.
    PubMed     Abstract available
    
    
    
49. WEI C, Su L, Liu L, Zhou D, et al
    Combined oral PI3Kdelta inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial.
    Leuk Lymphoma. 2026 Mar 3:1-9. doi: 10.1080/10428194.2026.2631800.
    PubMed     Abstract available
    
    
    
50. GONG IY, Kuruvilla J
    Management of relapsed/refractory DLBCL in the era of novel agents and new approaches.
    Leuk Lymphoma. 2026;67:756-784.
    PubMed     Abstract available
    
    
    
51. KLEBANER D, Park NJ, Marar M, Frank M, et al
    Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
    Leuk Lymphoma. 2026;67:813-820.
    PubMed     Abstract available
    
    
    February 2026
52. LIA K, Galleberg RB, Rostoft S, Jorgensen RRK, et al
    Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey.
    Leuk Lymphoma. 2026 Feb 28:1-11. doi: 10.1080/10428194.2026.2633180.
    PubMed     Abstract available
    
    
    
53. BACHY E, Harnett J, Prochazka K, Townsend W, et al
    Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.
    Leuk Lymphoma. 2026 Feb 24:1-12. doi: 10.1080/10428194.2026.2619500.
    PubMed     Abstract available
    
    
    
54. OHNO H, Maekawa F, Hayashida M, Nakagawa M, et al
    t(14;19)(q32;q13) breakpoints telomeric to BCL3 on 19q13.32 in B-cell lymphomas other than chronic lymphocytic leukemia and long-range structures of der(19)t(14;19) based on optical genome mapping.
    Leuk Lymphoma. 2026 Feb 22:1-11. doi: 10.1080/10428194.2026.2633186.
    PubMed     Abstract available
    
    
    
55. GUPTA Y, Hurst E, Publicover A, Jardine L, et al
    Glofitamab as a salvage therapy postallogenic hematopoietic stem cell transplant in relapsed-refractory Burkitt lymphoma.
    Leuk Lymphoma. 2026 Feb 5:1-3. doi: 10.1080/10428194.2026.2624667.
    PubMed    
    
    
    
56. YOSHIDA K, Mushino T, Tanaka K, Kosako H, et al
    Distribution of CD30-positive tumor cell proportions in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2622526.
    PubMed    
    
    
    
57. GOKHALE M, Chan PK, Jiang W, Levin R, et al
    Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: a real-world evidence study.
    Leuk Lymphoma. 2026;67:582-591.
    PubMed     Abstract available
    
    
    
58. BHABHA F, Prince HM, Campbell B, Van Der Weyden C, et al
    Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.
    Leuk Lymphoma. 2026;67:536-555.
    PubMed     Abstract available
    
    
    January 2026
59. BANEGAS DE, Ferrarini I, Bernardelli A, Moioli A, et al
    Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
    Leuk Lymphoma. 2026 Jan 29:1-5. doi: 10.1080/10428194.2026.2621825.
    PubMed    
    
    
    
60. CHIRIAC R, Donzel M, Mauduit C, Gerland LM, et al
    Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.
    Leuk Lymphoma. 2026 Jan 29:1-4. doi: 10.1080/10428194.2026.2620550.
    PubMed    
    
    
    
61. PHILLIPS T, Zhou Z, Gutierrez C, Shao A, et al
    Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024).
    Leuk Lymphoma. 2026 Jan 19:1-11. doi: 10.1080/10428194.2025.2604300.
    PubMed     Abstract available
    
    
    
62. SUKE SG, Prince HM
    Epcoritamab for diffuse large B-cell lymphoma in a dialysis-dependent patient.
    Leuk Lymphoma. 2026 Jan 19:1-3. doi: 10.1080/10428194.2026.2617970.
    PubMed    
    
    
    
63. ABALO KD, Trab T, Baech J, Ekberg S, et al
    Survival in mantle cell lymphoma patients burdened by a second primary malignancy.
    Leuk Lymphoma. 2026 Jan 9:1-11. doi: 10.1080/10428194.2025.2606211.
    PubMed     Abstract available
    
    
    
64. GUO J, Li M, Zhang L, Zhang Q, et al
    Clinical outcomes of modified busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for T-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2026 Jan 5:1-14. doi: 10.1080/10428194.2025.2605516.
    PubMed     Abstract available
    
    
    
65. YU Y, Xiang Z, Hou X, Hu K, et al
    Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis.
    Leuk Lymphoma. 2026;67:123-134.
    PubMed     Abstract available
    
    
    
66. SAITO Y, Oda T, Nakanishi S, Ota M, et al
    Safety profiles in elderly patients with DLBCL on first-line Pola-R-CHP: a claims database study in Japan.
    Leuk Lymphoma. 2026;67:135-147.
    PubMed     Abstract available
    
    
    
67. RIBER HANSEN EV, Dennis S, Braendstrup P, Eriksen JO, et al
    Discordant cell-of-origin in refractory/relapsed LBCL at diagnosis and relapse.
    Leuk Lymphoma. 2026;67:377-384.
    PubMed     Abstract available
    
    
    December 2025
68. GRIBBEN JG, Palomba ML, Limbrick-Oldfield E, Palivela M, et al
    Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.
    Leuk Lymphoma. 2025 Dec 30:1-5. doi: 10.1080/10428194.2025.2604306.
    PubMed    
    
    
    
69. VITHANAGE PG, Rafiq M, Drosdowsky A, Ramsay G, et al
    Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review.
    Leuk Lymphoma. 2025 Dec 30:1-25. doi: 10.1080/10428194.2025.2598663.
    PubMed     Abstract available
    
    
    
70. MOHAMMED SALEH MF, Kotb A, Alamer A, Albabtain AA, et al
    T-cell/histiocyte-rich large B-cell lymphoma, insights into prognosis and treatment complexity in the context of immunotherapeutics.
    Leuk Lymphoma. 2025 Dec 29:1-7. doi: 10.1080/10428194.2025.2607549.
    PubMed     Abstract available
    
    
    
71. STAFYLIDIS C, Lakiotaki E, Rougala N, Giannakopoulou N, et al
    Reclassifying T-cell lymphomas in human T-lymphotropic virus 1 carriers: a familial case of adult T-cell leukemia/lymphoma with diagnostic and pathogenetic implications.
    Leuk Lymphoma. 2025 Dec 25:1-5. doi: 10.1080/10428194.2025.2606948.
    PubMed    
    
    
    
72. MATSUMOTO S, Kurihara Y, Masuda Y, Nara K, et al
    Prognostic impact of procarbazine in R-MPV followed by reduced-dose whole-brain radiotherapy and cytarabine for primary central nervous system lymphoma.
    Leuk Lymphoma. 2025 Dec 22:1-9. doi: 10.1080/10428194.2025.2604305.
    PubMed     Abstract available
    
    
    
73. LIU J, Zhou J, Xi Z, Liu K, et al
    Survival outcomes and failure patterns in stage I/II extranodal NK/T-cell lymphoma after involved site radiotherapy with asparaginase-based chemotherapy-a retrospective study.
    Leuk Lymphoma. 2025 Dec 13:1-9. doi: 10.1080/10428194.2025.2600639.
    PubMed     Abstract available
    
    
    
74. STEGEMANN M, Macherndl-Spandl S, Mairhofer M, Kaltenbrunner S, et al
    Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 x CD3 bispecific antibody for refractory Burkitt lymphoma, a case report.
    Leuk Lymphoma. 2025 Dec 8:1-5. doi: 10.1080/10428194.2025.2591779.
    PubMed    
    
    
    
75. OLUWOLE OO, Wade SW, Smith NJ, Spousta T, et al
    Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.
    Leuk Lymphoma. 2025 Dec 8:1-5. doi: 10.1080/10428194.2025.2584686.
    PubMed    
    
    
    
76. FAISAL MS, Anampa Guzman A, Attwood K, Torka P, et al
    Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience.
    Leuk Lymphoma. 2025 Dec 5:1-5. doi: 10.1080/10428194.2025.2589932.
    PubMed    
    
    
    
77. BRAUN T, Keppel M, Dechow A, Pflug N, et al
    Characteristics, patterns of care and outcomes of patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis.
    Leuk Lymphoma. 2025 Dec 5:1-4. doi: 10.1080/10428194.2025.2594062.
    PubMed    
    
    
    
78. KAMINSKY A, Fahmy LM, Bilgrami Z, Yang HR, et al
    From dimensions through dynamics to outcomes - lymph nodes and skin assessments predict CTCL outcomes.
    Leuk Lymphoma. 2025;66:2528-2536.
    PubMed     Abstract available
    
    
    
79. ANGELUCCI E, Deconinck E, Benoit TM, Braitsch K, et al
    Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2489-2497.
    PubMed     Abstract available
    
    
    
80. PARTANEN A, Kinnunen T, Jantunen E
    Graft-versus-tumor effect in autologous setting: fact or fallacy?
    Leuk Lymphoma. 2025;66:2388-2396.
    PubMed     Abstract available
    
    
    
81. LANE AA, Papayannidis C, Angelucci E, McCloskey J, et al
    Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2569-2577.
    PubMed     Abstract available
    
    
    November 2025
82. SUN Y, Aviv H
    Neuroendocrine transdifferentiation of aggressive B-cell leukemia/lymphoma post CAR-T therapy.
    Leuk Lymphoma. 2025 Nov 19:1-4. doi: 10.1080/10428194.2025.2589375.
    PubMed    
    
    
    
83. DENG C, Agarwal N, Sindel AD
    Emerging first-line treatment approaches for mantle cell lymphoma.
    Leuk Lymphoma. 2025 Nov 17:1-11. doi: 10.1080/10428194.2025.2586079.
    PubMed     Abstract available
    
    
    
84. DADASHOVA A, Aliyeva G, Mamedov M, Melikova L, et al
    Homocysteine-driven oxidative stress in pediatric lymphoma: a cross-sectional study of metabolic and genetic modulators.
    Leuk Lymphoma. 2025 Nov 11:1-10. doi: 10.1080/10428194.2025.2586081.
    PubMed     Abstract available
    
    
    
85. TOUMEH N, Larson M, Negaard B, Casulo C, et al
    Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.
    Leuk Lymphoma. 2025 Nov 3:1-8. doi: 10.1080/10428194.2025.2582721.
    PubMed     Abstract available
    
    
    October 2025
86. REESE M, Hatfield J, Zamora C, Dittus C, et al
    Nivolumab with doxorubicin, vinblastine, and dacarbazine for the frontline treatment of central nervous system classical Hodgkin lymphoma.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2577256.
    PubMed    
    
    
    
87. LOPEDOTE P, Shouse G, Chen L, Smith DL, et al
    Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2566316.
    PubMed    
    
    
    
88. PICHARDO-RODRIGUEZ R, Vela-Ruiz JM, Villela L, Torres Viera MA, et al
    Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose-response evidence.
    Leuk Lymphoma. 2025 Oct 27:1-13. doi: 10.1080/10428194.2025.2566980.
    PubMed     Abstract available
    
    
    
89. DING W, Li A, Sun M, Xiong Y, et al
    CD19 CAR-T induces complete and durable remission in cold agglutinin syndrome associated relapse and refractory diffuse large B cell lymphoma.
    Leuk Lymphoma. 2025 Oct 26:1-3. doi: 10.1080/10428194.2025.2573873.
    PubMed    
    
    
    
90. LAZIC T, Barbieri E, Luminari S
    The emerging role of tafasitamab in follicular lymphoma.
    Leuk Lymphoma. 2025 Oct 15:1-10. doi: 10.1080/10428194.2025.2560083.
    PubMed     Abstract available
    
    
    
91. HORI Y, Hosoi H, Osuga M, Iwamoto R, et al
    Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA.
    Leuk Lymphoma. 2025 Oct 15:1-11. doi: 10.1080/10428194.2025.2556961.
    PubMed     Abstract available
    
    
    
92. LU X, Zhao L, Guo S, Chen N, et al
    MiR-22-3p regulates the SIRT1/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells.
    Leuk Lymphoma. 2025 Oct 15:1-13. doi: 10.1080/10428194.2025.2568186.
    PubMed     Abstract available
    
    
    
93. HESIUS EAM, Stewart JP, Kroeze LI, van der Spek E, et al
    Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.
    Leuk Lymphoma. 2025 Oct 13:1-14. doi: 10.1080/10428194.2025.2556177.
    PubMed     Abstract available
    
    
    
94. GUPTA S, Bachanova V
    CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence.
    Leuk Lymphoma. 2025 Oct 10:1-13. doi: 10.1080/10428194.2025.2560082.
    PubMed     Abstract available
    
    
    
95. SAKUMA H, Narita K, Tabata R, Fujii F, et al
    Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation.
    Leuk Lymphoma. 2025 Oct 8:1-8. doi: 10.1080/10428194.2025.2568742.
    PubMed     Abstract available
    
    
    
96. WATRIN T, Seifert M, Dietrich S
    The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
    Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
    PubMed     Abstract available
    
    
    
97. MASUCCI L, Kuruvilla J, Sander B, Prica A, et al
    Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada.
    Leuk Lymphoma. 2025;66:1875-1883.
    PubMed     Abstract available
    
    
    
98. ZHONG M, Liu H, Gui R, Zhang J, et al
    Progression of disease within 6 months: revised early disease progression threshold for ENKTL.
    Leuk Lymphoma. 2025;66:1893-1902.
    PubMed     Abstract available
    
    
    September 2025
99. ELGHAWY O, Swami N, Hing ZA, Barta SK, et al
    Advances in T-cell lymphomas and risk factors for CNS involvement.
    Leuk Lymphoma. 2025;66:1583-1602.
    PubMed     Abstract available
    
    
    
100. SHAH B, Challagulla S, Xu S, Williams R, et al
     Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
     Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2541911.
     PubMed     Abstract available
     
     
     August 2025
101. MEEUWES FO, Serroukh YIM, van der Poel MWM, Plattel WJ, et al
     Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives.
     Leuk Lymphoma. 2025 Aug 28:1-16. doi: 10.1080/10428194.2025.2545927.
     PubMed     Abstract available
     
     
     
102. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
     Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
     Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
     PubMed    
     
     
     
103. ISKIERKA-JAZDZEWSKA E, Kim WS, Cho SG, Kim TM, et al
     Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
     Leuk Lymphoma. 2025 Aug 20:1-12. doi: 10.1080/10428194.2025.2535694.
     PubMed     Abstract available
     
     
     
104. MATARASSO GREENFELD S, Dmitrienko S, Shrier I, Deschenes JL, et al
     Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort.
     Leuk Lymphoma. 2025 Aug 18:1-4. doi: 10.1080/10428194.2025.2542943.
     PubMed    
     
     
     
105. TOLU SS, Gribbin C, Chen Z, Seshadri MR, et al
     Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
     Leuk Lymphoma. 2025 Aug 14:1-11. doi: 10.1080/10428194.2025.2540437.
     PubMed     Abstract available
     
     
     
106. JEFFREY A, Favaloro J, Wolyncewicz G, Horgan L, et al
     Spontaneous remission of Epstein-Barr virus positive diffuse large B-cell lymphoma after relapse post axicabtagene ciloleucel chimeric antigen receptor T-cell therapy.
     Leuk Lymphoma. 2025 Aug 12:1-5. doi: 10.1080/10428194.2025.2545928.
     PubMed    
     
     
     
107. GORDON ER, Tolu S, Lapolla BA, Trager MH, et al
     Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.
     Leuk Lymphoma. 2025 Aug 11:1-8. doi: 10.1080/10428194.2025.2542941.
     PubMed     Abstract available
     
     
     
108. ZHOU X, Ling Y, Ma J, Lin Z, et al
     Clinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients.
     Leuk Lymphoma. 2025 Aug 8:1-12. doi: 10.1080/10428194.2025.2541016.
     PubMed     Abstract available
     
     
     
109. SHARIFF N, Chun FJ, Parsons SK, Hodgson DC, et al
     The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review.
     Leuk Lymphoma. 2025 Aug 8:1-13. doi: 10.1080/10428194.2025.2531154.
     PubMed     Abstract available
     
     
     
110. SUPERDOCK MA, Rimsza LM, Wallace DS, Strawderman M, et al
     Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study.
     Leuk Lymphoma. 2025 Aug 6:1-4. doi: 10.1080/10428194.2025.2539231.
     PubMed    
     
     
     
111. XIAO A, Chen L, Pak S, Lee B, et al
     Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma.
     Leuk Lymphoma. 2025 Aug 5:1-9. doi: 10.1080/10428194.2025.2540442.
     PubMed     Abstract available
     
     
     
112. FUJINO T, Okamoto H, Nishiyama D, Hayata H, et al
     Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
     Leuk Lymphoma. 2025;66:1425-1436.
     PubMed     Abstract available
     
     
     July 2025
113. CHAUDHRY AL, Chevez-Barrios P, Strati P
     Zanubrutinib is active for the treatment of relapsed primary vitreoretinal lymphoma.
     Leuk Lymphoma. 2025 Jul 26:1-4. doi: 10.1080/10428194.2025.2539227.
     PubMed    
     
     
     
114. ABRAMSON JS, Kamdar M, Liu FF, Crotta A, et al
     Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma.
     Leuk Lymphoma. 2025 Jul 24:1-14. doi: 10.1080/10428194.2025.2532674.
     PubMed     Abstract available
     
     
     
115. KITAMURA A, Shiroshita K, Fujita S, Kudo H, et al
     Unexpected progression of lymphoplasmacytic lymphoma with TP53 deletion after treatment for concurrent multiple myeloma with IGH::CCND1.
     Leuk Lymphoma. 2025 Jul 24:1-5. doi: 10.1080/10428194.2025.2536126.
     PubMed    
     
     
     
116. HU W, Landgren O, Bassig BA, Purdue MP, et al
     Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study.
     Leuk Lymphoma. 2025 Jul 16:1-8. doi: 10.1080/10428194.2025.2524505.
     PubMed     Abstract available
     
     
     
117. WU Y, Ke Q, Liu B, Luo W, et al
     KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
     Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
     PubMed    
     
     
     
118. ISMAYILOV R, Ozdede M, Uner A, Barista I, et al
     Machine learning-based risk prediction model for central nervous system involvement in diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2025 Jul 12:1-10. doi: 10.1080/10428194.2025.2526793.
     PubMed     Abstract available
     
     
     
119. IZUTSU K, Akahane D, Toubai T, Saito T, et al
     Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
     Leuk Lymphoma. 2025 Jul 9:1-9. doi: 10.1080/10428194.2025.2525983.
     PubMed     Abstract available
     
     
     
120. ANDREADIS C, Bobek O, Hsi ED, Fenske TS, et al
     Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup doub
     Leuk Lymphoma. 2025 Jul 9:1-10. doi: 10.1080/10428194.2025.2525982.
     PubMed     Abstract available
     
     
     
121. MEEUWES FO, Brink M, van der Poel MWM, Serroukh YIM, et al
     Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands.
     Leuk Lymphoma. 2025 Jul 9:1-7. doi: 10.1080/10428194.2025.2530167.
     PubMed     Abstract available
     
     
     
122. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
     Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
     Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
     PubMed    
     
     
     
123. LUTTWAK E, Robin ET, Drill E, Boardman A, et al
     Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
     Leuk Lymphoma. 2025;66:1276-1283.
     PubMed     Abstract available
     
     
     
124. MAURER K, Jacobson CA
     T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies.
     Leuk Lymphoma. 2025;66:1189-1197.
     PubMed     Abstract available
     
     
     June 2025
125. DERENZINI E, Gibb A, Kwiatek M, Strati P, et al
     Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.
     Leuk Lymphoma. 2025 Jun 30:1-13. doi: 10.1080/10428194.2025.2520440.
     PubMed     Abstract available
     
     
     
126. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
     Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
     PubMed     Abstract available
     
     
     
127. PREM SUDHA S, Shehata A, Al-Ali F, Abdelfattah N, et al
     Use of doxorubicin is not associated with hemolytic complications in severely G6PD deficient patients with lymphoma.
     Leuk Lymphoma. 2025 Jun 24:1-7. doi: 10.1080/10428194.2025.2521654.
     PubMed     Abstract available
     
     
     
128. KURUVILLA J, Modi D, Santoro A, Paszkiewicz-Kozik E, et al
     Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.
     Leuk Lymphoma. 2025 Jun 23:1-10. doi: 10.1080/10428194.2025.2502805.
     PubMed     Abstract available
     
     
     
129. DANDAMUDI DB, Konieczna IM, Calabrese KM, Wielgos-Bonvallet M, et al
     Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.
     Leuk Lymphoma. 2025 Jun 18:1-12. doi: 10.1080/10428194.2025.2504719.
     PubMed     Abstract available
     
     
     
130. LIN MH, Weiss J, Phillips TJ, Sano D, et al
     Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.
     Leuk Lymphoma. 2025 Jun 9:1-13. doi: 10.1080/10428194.2025.2506498.
     PubMed     Abstract available
     
     
     
131. LAKHOTIA R, Melani C, Dunleavy K, Pittaluga S, et al
     Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.
     Leuk Lymphoma. 2025;66:1088-1099.
     PubMed     Abstract available
     
     
     May 2025
132. RASMUSSEN LA, Vedsted P, Jensen H, Frederiksen H, et al
     Lymphoma: factors associated with unplanned diagnostic pathways and survival -a nationwide Danish register-based cohort study.
     Leuk Lymphoma. 2025 May 27:1-12. doi: 10.1080/10428194.2025.2508299.
     PubMed     Abstract available
     
     
     
133. MESTNIK S, Marley AR, Lu Z, Turcotte LM, et al
     Childhood body mass index at diagnosis and its association with non-Hodgkin lymphoma in the United States: a children's oncology group data analysis project.
     Leuk Lymphoma. 2025 May 26:1-6. doi: 10.1080/10428194.2025.2506502.
     PubMed     Abstract available
     
     
     
134. BUCALOIU A, Jamshidi P, Dixit K, Sukhanova M, et al
     Diagnostic utility of plasma circulating tumor DNA (ctDNA) in primary large B-cell lymphoma of the central nervous system (PCNS-LBCL): A paradigm shift?
     Leuk Lymphoma. 2025 May 23:1-4. doi: 10.1080/10428194.2025.2508298.
     PubMed    
     
     
     
135. HILL BT, Torka P, Hernandez-Ilizaliturri F, Dean R, et al
     Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.
     Leuk Lymphoma. 2025 May 21:1-10. doi: 10.1080/10428194.2025.2504156.
     PubMed     Abstract available
     
     
     
136. ROBAK E, Braun M, Robak T
     A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type.
     Leuk Lymphoma. 2025 May 20:1-12. doi: 10.1080/10428194.2025.2506503.
     PubMed     Abstract available
     
     
     
137. BALAN K, Aslan M, Ayhan EA, Akin S, et al
     Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions.
     Leuk Lymphoma. 2025 May 9:1-3. doi: 10.1080/10428194.2025.2503464.
     PubMed    
     
     
     
138. CRUZ CA, Rodriguez ER, Thawani M, Mazer M, et al
     Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.
     Leuk Lymphoma. 2025 May 8:1-7. doi: 10.1080/10428194.2025.2499607.
     PubMed     Abstract available
     
     
     
139. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
     Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
     Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
     PubMed    
     
     
     
140. HAYDON MD, Hwang AE, Wade NB, Wang J, et al
     Adverse late outcomes in long-term survivors of young adult Hodgkin lymphoma (YAHL) compared to their unaffected co-twins.
     Leuk Lymphoma. 2025 May 1:1-10. doi: 10.1080/10428194.2025.2476664.
     PubMed     Abstract available
     
     
     April 2025
141. PUCKRIN R
     The paradox of the spleen: is it a nodal or extranodal site of lymphoma?
     Leuk Lymphoma. 2025 Apr 22:1-3. doi: 10.1080/10428194.2025.2495112.
     PubMed    
     
     
     
142. MAHMOUDJAFARI Z, Di Maio D, Li J, Rosettie KL, et al
     Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysis(double dagger).
     Leuk Lymphoma. 2025 Apr 9:1-8. doi: 10.1080/10428194.2025.2486437.
     PubMed     Abstract available
     
     
     
143. ANDERSON E, Choi Y, Buchsbaum RJ, Klein A, et al
     Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.
     Leuk Lymphoma. 2025 Apr 8:1-10. doi: 10.1080/10428194.2025.2484367.
     PubMed     Abstract available
     
     
     
144. WANG W, Chen M, Li J, Liu J, et al
     Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma.
     Leuk Lymphoma. 2025 Apr 2:1-6. doi: 10.1080/10428194.2025.2484365.
     PubMed     Abstract available
     
     
     March 2025
145. GARG M, Satija A, Song Y, Sarpong EM, et al
     Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data.
     Leuk Lymphoma. 2025 Mar 31:1-10. doi: 10.1080/10428194.2025.2482136.
     PubMed     Abstract available
     
     
     
146. VODICKA P, Masar M, Benesova K, Koren J, et al
     The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis.
     Leuk Lymphoma. 2025 Mar 31:1-7. doi: 10.1080/10428194.2025.2475327.
     PubMed     Abstract available
     
     
     
147. OWEN C, Mojtabavi A, Buckland T, Dean M, et al
     Analysis of a cancer-care based diagnosis program for lymphoma.
     Leuk Lymphoma. 2025 Mar 26:1-6. doi: 10.1080/10428194.2025.2482890.
     PubMed     Abstract available
     
     
     
148. ONISHI A, Miyagawa-Hayashino A, Okamoto H, Fujino T, et al
     Phosphorylation status and prognostic impacts of RSK2, PDPK1, and AKT in malignant lymphoma.
     Leuk Lymphoma. 2025 Mar 25:1-12. doi: 10.1080/10428194.2025.2482891.
     PubMed     Abstract available
     
     
     
149. ROBAK T, Pluta A, Robak P, Janus A, et al
     Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
     Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
     PubMed     Abstract available
     
     
     
150. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
     Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
     PubMed     Abstract available
     
     
     
151. DAUNOV M, Deng C
     Twice the trouble, half the fun: twin study suggests future direction for young adults with Hodgkin lymphoma.
     Leuk Lymphoma. 2025 Mar 14:1-3. doi: 10.1080/10428194.2025.2476650.
     PubMed    
     
     
     
152. STEWART C, Owen C, Street L, Hay K, et al
     Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate.
     Leuk Lymphoma. 2025 Mar 11:1-4. doi: 10.1080/10428194.2025.2477725.
     PubMed    
     
     
     
153. MAJOR A, Palese M, Jones A, Goes M, et al
     Patient and care partner perspectives on treatment decision-making in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): a Global nLPHL One Working Group (GLOW) study.
     Leuk Lymphoma. 2025 Mar 10:1-5. doi: 10.1080/10428194.2025.2474080.
     PubMed    
     
     
     
154. TUCCI A, Re A, Pagani C, Marcheselli L, et al
     A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.
     Leuk Lymphoma. 2025 Mar 8:1-9. doi: 10.1080/10428194.2025.2471499.
     PubMed     Abstract available
     
     
     
155. LEE J, Song SY, Shin YS, Kim SW, et al
     Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.
     Leuk Lymphoma. 2025 Mar 6:1-8. doi: 10.1080/10428194.2025.2470777.
     PubMed     Abstract available
     
     
     
156. KIM MJ, Cho J, Kim WS, Kim SJ, et al
     Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma.
     Leuk Lymphoma. 2025 Mar 3:1-12. doi: 10.1080/10428194.2025.2471500.
     PubMed     Abstract available
     
     
     February 2025
157. GURUMURTHI A, Henshaw L, Falchi L, Moskowitz A, et al
     Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naive Hodgkin lymphoma.
     Leuk Lymphoma. 2025 Feb 24:1-4. doi: 10.1080/10428194.2025.2470776.
     PubMed    
     
     
     
158. ABEYAKOON C, Ting E, Khan S, Maganti M, et al
     Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.
     Leuk Lymphoma. 2025 Feb 21:1-5. doi: 10.1080/10428194.2025.2467801.
     PubMed    
     
     
     
159. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
     Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
     Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
     PubMed    
     
     
     
160. GAMBELLA M, Carlomagno S, Raiola AM, Sivori S, et al
     (CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.
     Leuk Lymphoma. 2025 Feb 13:1-9. doi: 10.1080/10428194.2025.2456096.
     PubMed     Abstract available
     
     
     
161. FREY C, Etminan M
     Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma.
     Leuk Lymphoma. 2025 Feb 12:1-3. doi: 10.1080/10428194.2025.2461663.
     PubMed     Abstract available
     
     
     
162. HORWITZ SM, Feldman TA, Ye JC, Khodadoust MS, et al
     Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
     Leuk Lymphoma. 2025 Feb 8:1-11. doi: 10.1080/10428194.2025.2455489.
     PubMed     Abstract available
     
     
     
163. XIONG S, Zhang S, Yue N, Cao J, et al
     CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges.
     Leuk Lymphoma. 2025 Feb 3:1-13. doi: 10.1080/10428194.2025.2458214.
     PubMed     Abstract available
     
     
     January 2025
164. FEDELE PL, Opat S
     Indolent lymphoma: addressing the needs of survivors.
     Leuk Lymphoma. 2025 Jan 28:1-15. doi: 10.1080/10428194.2025.2456970.
     PubMed     Abstract available
     
     
     
165. GAULIN C, Jain P, Nair R, Iyer SP, et al
     Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
     Leuk Lymphoma. 2025 Jan 21:1-5. doi: 10.1080/10428194.2025.2454540.
     PubMed    
     
     
     
166. CENCINI E, Palazzo M, Dardanis D, Lucco Navei G, et al
     Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).
     Leuk Lymphoma. 2025 Jan 21:1-10. doi: 10.1080/10428194.2025.2456094.
     PubMed     Abstract available
     
     
     
167. WANG Y, Han J, Yin S, Yang S, et al
     Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system.
     Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2451066.
     PubMed     Abstract available
     
     
     
168. BENNETT R, Juneja M, Anderson MA, Minson A, et al
     Routine magnetic resonance central nervous system imaging may be avoided in high-risk systemic diffuse large B-cell lymphoma with negative cerebrospinal fluid analyses.
     Leuk Lymphoma. 2025 Jan 14:1-4. doi: 10.1080/10428194.2025.2451725.
     PubMed    
     
     
     
169. RUSCONI C, Barone A, Visentin A, Bianchi B, et al
     Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.
     Leuk Lymphoma. 2025 Jan 11:1-9. doi: 10.1080/10428194.2024.2446609.
     PubMed     Abstract available
     
     
     
170. HARRIS W, Cao Y, Morschhauser F, Salles G, et al
     gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles.
     Leuk Lymphoma. 2025 Jan 10:1-8. doi: 10.1080/10428194.2024.2446613.
     PubMed     Abstract available
     
     
     
171. VARTANOV AR, Hasler JS, Handorf EA, Frosch ZAK, et al
     Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2025 Jan 8:1-4. doi: 10.1080/10428194.2025.2450091.
     PubMed    
     
     
     
172. GAO Y, Zhang L, Gao S, Yang Y, et al
     Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial.
     Leuk Lymphoma. 2025 Jan 7:1-11. doi: 10.1080/10428194.2024.2439525.
     PubMed     Abstract available
     
     
     
173. GRUNBLATT E, Meng Z, Baldridge AS, Patel NP, et al
     Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.
     Leuk Lymphoma. 2025 Jan 7:1-11. doi: 10.1080/10428194.2024.2448713.
     PubMed     Abstract available
     
     
     
174. LUTTWAK E, Kumar A, Salles G
     Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.
     Leuk Lymphoma. 2025 Jan 5:1-12. doi: 10.1080/10428194.2024.2447371.
     PubMed     Abstract available
     
     
     
175. JIN J, Meng DD, Wen Y, Zhang QL, et al
     PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.
     Leuk Lymphoma. 2025 Jan 5:1-10. doi: 10.1080/10428194.2024.2447888.
     PubMed     Abstract available
     
     
     
176. ALMEIDA PM, Relander T, Linden O
     Salvage therapy for Burkitt lymphoma with glofitamab: a case report.
     Leuk Lymphoma. 2025 Jan 3:1-4. doi: 10.1080/10428194.2024.2447882.
     PubMed    
     
     
     
177. EICHENAUER DA, Borchmann P
     Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.
     Leuk Lymphoma. 2025 Jan 2:1-8. doi: 10.1080/10428194.2024.2447886.
     PubMed     Abstract available
     
     
     December 2024
178. NG LCK, Ong SY, Huang X, Ghosh A, et al
     Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study.
     Leuk Lymphoma. 2024 Dec 28:1-7. doi: 10.1080/10428194.2024.2446615.
     PubMed     Abstract available
     
     
     
179. OTHMAN T, Marquez-Arreguin G, Esteghamat N, Tuscano J, et al
     A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma.
     Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2443552.
     PubMed    
     
     
     
180. TINAJERO J, Markary T, Ngo D, Kambhampati Thiruvengadam S, et al
     Glofitamab in patients with HIV-associated B-cell lymphoma.
     Leuk Lymphoma. 2024 Dec 23:1-4. doi: 10.1080/10428194.2024.2444470.
     PubMed    
     
     
     
181. GRIGG S, Lade S, Ryland G, Grimmond S, et al
     Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.
     Leuk Lymphoma. 2024 Dec 22:1-4. doi: 10.1080/10428194.2024.2443561.
     PubMed    
     
     
     
182. KIM K, Chihara D
     The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma.
     Leuk Lymphoma. 2024 Dec 17:1-11. doi: 10.1080/10428194.2024.2436606.
     PubMed     Abstract available
     
     
     
183. MUNOZ J, Tsang M, Wang Y, Phillips T, et al
     Challenges of treating mantle cell lymphoma in older adults.
     Leuk Lymphoma. 2024 Dec 11:1-18. doi: 10.1080/10428194.2024.2431563.
     PubMed     Abstract available
     
     
     
184. SHUMILOV E, Levien L, Mazzeo P, Jung W, et al
     Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning.
     Leuk Lymphoma. 2024 Dec 11:1-12. doi: 10.1080/10428194.2024.2438805.
     PubMed     Abstract available
     
     
     
185. ANDERSEN MD, Wolter K, Enemark MH, Lauridsen KL, et al
     Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.
     Leuk Lymphoma. 2024 Dec 3:1-12. doi: 10.1080/10428194.2024.2434170.
     PubMed     Abstract available
     
     
     
186. TEOH XY, Mashor Mansor M, Mohd Affandi A, Awang A, et al
     Spontaneous regression of cutaneous T cell lymphoma in an HIV-positive patient.
     Leuk Lymphoma. 2024 Dec 2:1-2. doi: 10.1080/10428194.2024.2433616.
     PubMed    
     
     
     
187. GORDON ER, Trager MH, Kwinta BD, Stonesifer CJ, et al
     Maintenance therapy for CTCL: importance for prevention of disease progression.
     Leuk Lymphoma. 2024;65:1883-1890.
     PubMed     Abstract available
     
     
     
188. KURUCU N, Kutluk T, Saglam A, Cagdas D, et al
     Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity.
     Leuk Lymphoma. 2024;65:1875-1882.
     PubMed     Abstract available
     
     
     
189. MINA A
     Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
     Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
     PubMed    
     
     
     
190. JAMAL E, Poynton E, Elbogdady M, Shamaa S, et al
     Prospects for liquid biopsy approaches in lymphomas.
     Leuk Lymphoma. 2024;65:1923-1933.
     PubMed     Abstract available
     
     
     
191. LANIER CM, Razavian NB, Smith S, D'Agostino RB Jr, et al
     The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303.
     Leuk Lymphoma. 2024;65:2199-2206.
     PubMed     Abstract available
     
     
     
192. SIMONSEN MR, Haunstrup LM, Severinsen FT, Jensen RK, et al
     The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study.
     Leuk Lymphoma. 2024;65:2173-2181.
     PubMed     Abstract available
     
     
     November 2024
193. DESCHENES-SIMARD X, Pennisi M, Perales MA, Shah GL, et al
     Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
     Leuk Lymphoma. 2024 Nov 20:1-6. doi: 10.1080/10428194.2024.2430703.
     PubMed    
     
     
     
194. MISHRA P, Bhurani D, Khan MA, Nidhi, et al
     Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy.
     Leuk Lymphoma. 2024 Nov 15:1-13. doi: 10.1080/10428194.2024.2424373.
     PubMed     Abstract available
     
     
     
195. SORIGUE M
     Follow-up in patients with lymphoma: a call for an evidence-based approach.
     Leuk Lymphoma. 2024 Nov 15:1-4. doi: 10.1080/10428194.2024.2426053.
     PubMed    
     
     
     October 2024
196. THIEBLEMONT C, Wahlin BE, Mohseninejad L, Wang K, et al
     Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.
     Leuk Lymphoma. 2024 Oct 24:1-10. doi: 10.1080/10428194.2024.2416577.
     PubMed     Abstract available
     
     
     
197. FASSER D, Lewis K, Leslie C, Cull G, et al
     Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era.
     Leuk Lymphoma. 2024 Oct 18:1-4. doi: 10.1080/10428194.2024.2416563.
     PubMed    
     
     
     
198. HAN J, McCall CM, Isom S, Smith WM, et al
     High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy.
     Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2414899.
     PubMed    
     
     
     
199. YANG L, Zeng LJ, Wang S, Wei LQ, et al
     Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing DeltaSUVlbm between baseline and interim (18)F-FDG PET/CT scans.
     Leuk Lymphoma. 2024 Oct 15:1-8. doi: 10.1080/10428194.2024.2416026.
     PubMed     Abstract available
     
     
     
200. SOMASUNDARAM E, Abramson JS
     Double hit lymphoma: contemporary understanding and practices.
     Leuk Lymphoma. 2024 Oct 8:1-8. doi: 10.1080/10428194.2024.2412295.
     PubMed     Abstract available
     
     
     
201. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
     Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
     PubMed     Abstract available
     
     
     September 2024
202. USTA S, Misura A, Rashedi I, Amitai I, et al
     Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2024 Sep 27:1-11. doi: 10.1080/10428194.2024.2403668.
     PubMed     Abstract available
     
     
     
203. FUREDER W, Skrabs C, Tobudic S
     Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab.
     Leuk Lymphoma. 2024 Sep 23:1-3. doi: 10.1080/10428194.2024.2404246.
     PubMed    
     
     
     
204. GURUMURTHI A, Bantilan KS, Hamlin PA, Kumar A, et al
     A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
     Leuk Lymphoma. 2024 Sep 20:1-4. doi: 10.1080/10428194.2024.2398658.
     PubMed    
     
     
     
205. ROBINSON S, Wu S, Lade S, Tam CS, et al
     CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma.
     Leuk Lymphoma. 2024 Sep 18:1-4. doi: 10.1080/10428194.2024.2404954.
     PubMed    
     
     
     
206. ANNIBALI O, Merli M, Minoia C, Mancuso S, et al
     Vaccination strategies for patients with lymphoma treated in early lines of therapies: a real-world practice survey among Fondazione Italiana Linfomi centers.
     Leuk Lymphoma. 2024 Sep 18:1-6. doi: 10.1080/10428194.2024.2405866.
     PubMed     Abstract available
     
     
     
207. MILSHTEYN L, Villamejor A, Merchant A, Lownik J, et al
     A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications.
     Leuk Lymphoma. 2024 Sep 18:1-7. doi: 10.1080/10428194.2024.2404253.
     PubMed     Abstract available
     
     
     
208. MEHTAP O, Toptas T, Dal MS, Karadag FK, et al
     A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients.
     Leuk Lymphoma. 2024 Sep 13:1-9. doi: 10.1080/10428194.2024.2395458.
     PubMed     Abstract available
     
     
     
209. DUFFLES G, Braga A, Silveira T, Novis Y, et al
     Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study.
     Leuk Lymphoma. 2024 Sep 10:1-7. doi: 10.1080/10428194.2024.2401098.
     PubMed     Abstract available
     
     
     
210. HARROP S, Dickinson M
     Eligibility for clinical trials in diffuse large B-cell lymphoma: are we sweating the small stuff?
     Leuk Lymphoma. 2024 Sep 5:1-3. doi: 10.1080/10428194.2024.2400217.
     PubMed    
     
     
     
211. BRAUN APG, Herrera A
     Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse.
     Leuk Lymphoma. 2024 Sep 3:1-8. doi: 10.1080/10428194.2024.2397072.
     PubMed     Abstract available
     
     
     
212. SHAULOV A, Gross Even-Zohar N, Aumann S, Haran A, et al
     Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature.
     Leuk Lymphoma. 2024 Sep 3:1-5. doi: 10.1080/10428194.2024.2396043.
     PubMed    
     
     
     
213. NARITA K, Okamoto A, Iba S, Tabata R, et al
     Analysis of the clinical features and outcomes of relapsed intravascular large B-cell lymphoma: a single center study.
     Leuk Lymphoma. 2024 Sep 3:1-4. doi: 10.1080/10428194.2024.2389213.
     PubMed    
     
     
     
214. BROCCOLI A, Margiotta-Casaluci G, Pagani C, Steffanoni S, et al
     Routine follow-up practices in patients with lymphoma: a nationwide survey by the Italian lymphoma foundation.
     Leuk Lymphoma. 2024 Sep 3:1-4. doi: 10.1080/10428194.2024.2396048.
     PubMed    
     
     
     
215. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
     Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
     Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
     PubMed     Abstract available
     
     
     
216. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
     RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
     Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
     PubMed     Abstract available
     
     
     August 2024
217. BRAND MVD, Tzankov A, Scheijde-Vermeulen M, Barbe E, et al
     The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?
     Leuk Lymphoma. 2024 Aug 29:1-4. doi: 10.1080/10428194.2024.2396542.
     PubMed    
     
     
     
218. FRUTOS DIAZ-ALEJO J, Morillo-Giles D, Diaz de la Pinta FJ, Manso R, et al
     New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis.
     Leuk Lymphoma. 2024 Aug 15:1-4. doi: 10.1080/10428194.2024.2390567.
     PubMed    
     
     
     
219. MENEZ S, Bourbon E, Gounot R, Tudesq JJ, et al
     CAR T-cells in very elderly (>/=80 years) lymphoma patients: a DESCAR-T analysis.
     Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2387731.
     PubMed    
     
     
     
220. ROSSETTI S, Juul SJ, van der Kaaij MAE, Fortpied C, et al
     Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials.
     Leuk Lymphoma. 2024 Aug 12:1-5. doi: 10.1080/10428194.2024.2390565.
     PubMed    
     
     
     
221. SOSA-ROMERO JT, Castillo-Martinez L, Gabutti-Thomas JA, Agreda-Va Squez GP, et al
     Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2024 Aug 2:1-10. doi: 10.1080/10428194.2024.2386591.
     PubMed     Abstract available
     
     
     
222. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
     Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
     Leuk Lymphoma. 2024;65:1100-1109.
     PubMed     Abstract available
     
     
     July 2024
223. LI Y, Sheng Q, Li J, Liu W, et al
     Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis.
     Leuk Lymphoma. 2024 Jul 31:1-14. doi: 10.1080/10428194.2024.2371500.
     PubMed     Abstract available
     
     
     
224. AHN J, Ouyang Y, Velasco G, Eapen A, et al
     A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin.
     Leuk Lymphoma. 2024 Jul 30:1-4. doi: 10.1080/10428194.2024.2385495.
     PubMed    
     
     
     
225. SORELLA S, Assanto GM, D'Elia GM, Annechini G, et al
     A case of posterior reversible encephalopathy syndrome (PRES) in an elderly patient with advanced classical Hodgkin Lymphoma during frontline treatment with brentuximab vedotin plus AVD.
     Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2383728.
     PubMed    
     
     
     
226. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
     Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
     Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
     PubMed    
     
     
     
227. JACOBSEN E, Plant A, Redd R, Armand P, et al
     A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma.
     Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2381651.
     PubMed     Abstract available
     
     
     
228. SANTOS LOURO L, Dimopoulos Y, Leventaki V, Vega F, et al
     Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14.
     Leuk Lymphoma. 2024 Jul 21:1-4. doi: 10.1080/10428194.2024.2381014.
     PubMed    
     
     
     
229. ADEUYAN O, Ouseph MM, Bao L, Kluk MJ, et al
     A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
     Leuk Lymphoma. 2024 Jul 17:1-5. doi: 10.1080/10428194.2024.2374455.
     PubMed    
     
     
     
230. CROMBIE JL, Jun M, Wang T, Mutebi A, et al
     Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2024 Jul 16:1-11. doi: 10.1080/10428194.2024.2371472.
     PubMed     Abstract available
     
     
     
231. VIJENTHIRA A, Li X, Crump M, Hay AE, et al
     Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.
     Leuk Lymphoma. 2024 Jul 9:1-8. doi: 10.1080/10428194.2024.2370437.
     PubMed     Abstract available
     
     
     
232. J WU J, Wade SW, Itani T, Castaigne JG, et al
     Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
     Leuk Lymphoma. 2024 Jul 8:1-14. doi: 10.1080/10428194.2024.2369653.
     PubMed     Abstract available
     
     
     
233. ZHANG JR, Wu SY, Jain P, Ok CY, et al
     Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center.
     Leuk Lymphoma. 2024 Jul 7:1-4. doi: 10.1080/10428194.2024.2374457.
     PubMed    
     
     
     
234. STEWART C, Owen C, Chua N, Peters A, et al
     Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.
     Leuk Lymphoma. 2024 Jul 5:1-4. doi: 10.1080/10428194.2024.2373323.
     PubMed    
     
     
     
235. ZHANG X, Chai Y, Lib C D W, Zhao P, et al
     Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?
     Leuk Lymphoma. 2024 Jul 5:1-6. doi: 10.1080/10428194.2024.2370433.
     PubMed     Abstract available
     
     
     June 2024
236. ZAIN J, Lunning M, Rosen S
     Experience of using venetoclax in relapsed T- cell lymphoma.
     Leuk Lymphoma. 2024 Jun 17:1-2. doi: 10.1080/10428194.2024.2363418.
     PubMed    
     
     
     
237. HONG D, Yin M, Li J, Deng Z, et al
     Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study.
     Leuk Lymphoma. 2024 Jun 11:1-11. doi: 10.1080/10428194.2024.2364830.
     PubMed     Abstract available
     
     
     
238. CHANG JE, Wang T, Kim K, Folstad M, et al
     Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
     PubMed     Abstract available
     
     
     
239. ANNIBALI O, Castellino A, Cenfra N, Ciccarone M, et al
     Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care).
     Leuk Lymphoma. 2024 Jun 7:1-8. doi: 10.1080/10428194.2024.2361358.
     PubMed     Abstract available
     
     
     
240. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
     A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
     Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
     PubMed    
     
     
     
241. LEWIS KL, Cheah CY
     The value of bispecific antibodies in relapsed and refractory DLBCL.
     Leuk Lymphoma. 2024;65:720-735.
     PubMed     Abstract available
     
     
     May 2024
242. HOROWITZ NA, Abed Al Wahad A, Bettman NP, Ringelstein-Harlev S, et al
     Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model.
     Leuk Lymphoma. 2024 May 23:1-4. doi: 10.1080/10428194.2024.2353879.
     PubMed    
     
     
     
243. LIU Y, Ma X, Wu X, Hou X, et al
     Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2.
     Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2343779.
     PubMed     Abstract available
     
     
     
244. DI M, Su CT, Cowan AJ, Gopal AK, et al
     Mitigating time toxicity in lymphoma and multiple myeloma.
     Leuk Lymphoma. 2024 May 15:1-12. doi: 10.1080/10428194.2024.2352086.
     PubMed     Abstract available
     
     
     
245. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
     Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
     Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
     PubMed    
     
     
     
246. CHERIAN S, Modelevsky L, Reiner AS, Grommes C, et al
     Treatment of methotrexate-refractory primary central nervous system lymphoma (PCNSL) at Memorial Sloan Kettering Cancer Center.
     Leuk Lymphoma. 2024 May 14:1-4. doi: 10.1080/10428194.2024.2343778.
     PubMed    
     
     
     
247. XING Y, Ye K, Li C, He J, et al
     Risk factors for treatment-related bone loss and osteoporosis in patients with follicular lymphoma.
     Leuk Lymphoma. 2024 May 6:1-9. doi: 10.1080/10428194.2024.2348113.
     PubMed     Abstract available
     
     
     
248. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
     Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
     Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
     PubMed     Abstract available
     
     
     
249. TABARI E, Lovejoy AF, Lin H, Bolen CR, et al
     NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.
     Leuk Lymphoma. 2024;65:618-628.
     PubMed     Abstract available
     
     
     
250. TUCCI A, Masina L, Luminari S
     Curative intent therapy for DLBCL in the elderly.
     Leuk Lymphoma. 2024;65:560-569.
     PubMed     Abstract available
     
     
     April 2024
251. VON ROEMELING C, Ferreri AJM, Soussain C, Tun HW, et al
     Targets and treatments in primary CNS lymphoma.
     Leuk Lymphoma. 2024 Apr 24:1-13. doi: 10.1080/10428194.2024.2342560.
     PubMed     Abstract available
     
     
     
252. MCNALLY GA, Aossey CM, Wiczer T, Sinnott LT, et al
     A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH +/- R: does HIV status matter?
     Leuk Lymphoma. 2024 Apr 22:1-7. doi: 10.1080/10428194.2024.2340051.
     PubMed     Abstract available
     
     
     
253. ALZAHRANI M, Villa D
     Management of relapsed/refractory mantle cell lymphoma.
     Leuk Lymphoma. 2024 Apr 18:1-11. doi: 10.1080/10428194.2024.2338851.
     PubMed     Abstract available
     
     
     
254. TA A, Kaur S, Mader M, Franklin K, et al
     The impact of race and ethnicity on diffuse large B-cell lymphoma outcomes within the veterans health administration (VHA).
     Leuk Lymphoma. 2024 Apr 15:1-10. doi: 10.1080/10428194.2024.2338856.
     PubMed     Abstract available
     
     
     
255. SANCHO JM, Abrisqueta P, Kumar A, Cordoba R, et al
     Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL?112).
     Leuk Lymphoma. 2024 Apr 10:1-11. doi: 10.1080/10428194.2024.2331626.
     PubMed     Abstract available
     
     
     
256. SCHAFF L, Nayak L, Grommes C
     Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
     Leuk Lymphoma. 2024 Apr 10:1-13. doi: 10.1080/10428194.2024.2333985.
     PubMed     Abstract available
     
     
     
257. CUI C, Feng C, Rosenthal N, Wade SW, et al
     Hospital healthcare resource utilization and costs for chimeric antigen T-cell therapy and autologous hematopoietic cell transplant in patients with large B-cell lymphoma in the United States.
     Leuk Lymphoma. 2024 Apr 3:1-10. doi: 10.1080/10428194.2024.2331084.
     PubMed     Abstract available
     
     
     
258. ATTYGALLE AD, Chan JKC, Coupland SE, Du MQ, et al
     The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update.
     Leuk Lymphoma. 2024;65:413-429.
     PubMed     Abstract available
     
     
     
259. ATALLAH-YUNES SA, Khurana A, Maurer M
     Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.
     Leuk Lymphoma. 2024;65:430-439.
     PubMed     Abstract available
     
     
     
260. SONG Y, Li J, Zhou K, Ke X, et al
     Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
     Leuk Lymphoma. 2024 Apr 1:1-6. doi: 10.1080/10428194.2024.2310141.
     PubMed     Abstract available
     
     
     March 2024
261. RYU TIGER YK, Jain S, Barta SK, Tolu S, et al
     Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
     Leuk Lymphoma. 2024 Mar 22:1-10. doi: 10.1080/10428194.2024.2329996.
     PubMed     Abstract available
     
     
     
262. TZIONI MM, Clipson A, Chen Z, Cucco F, et al
     Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma.
     Leuk Lymphoma. 2024 Mar 22:1-5. doi: 10.1080/10428194.2024.2332508.
     PubMed    
     
     
     
263. GAO LR, Wang X, Wu Y, Feng XL, et al
     Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
     Leuk Lymphoma. 2024 Mar 20:1-12. doi: 10.1080/10428194.2024.2329328.
     PubMed     Abstract available
     
     
     
264. ITCHAKI G, Jarhovsky O, Castillo JJ, Hassan H, et al
     Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.
     Leuk Lymphoma. 2024 Mar 19:1-7. doi: 10.1080/10428194.2024.2332499.
     PubMed     Abstract available
     
     
     
265. LI L, Yang W, Pan Y, Ye R, et al
     Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2024 Mar 18:1-16. doi: 10.1080/10428194.2024.2328227.
     PubMed     Abstract available
     
     
     
266. RAMALINGAM TR
     Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma.
     Leuk Lymphoma. 2024 Mar 14:1-2. doi: 10.1080/10428194.2024.2330707.
     PubMed    
     
     
     
267. GORDON MJ, Dubois S, Bryant B, Ng S, et al
     A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.
     Leuk Lymphoma. 2024 Mar 9:1-4. doi: 10.1080/10428194.2024.2326847.
     PubMed    
     
     
     
268. HILL BT, Chen Y, Jagadeesh D, Dean R, et al
     Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
     Leuk Lymphoma. 2024 Mar 8:1-6. doi: 10.1080/10428194.2024.2325636.
     PubMed     Abstract available
     
     
     
269. AKINGBEMI W, Kurtz G, Yegya-Raman N, Plastaras JP, et al
     Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
     Leuk Lymphoma. 2024 Mar 7:1-4. doi: 10.1080/10428194.2024.2322033.
     PubMed    
     
     
     
270. LEROY M, Deramoudt L, Pinturaud M, Demaret J, et al
     A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
     Leuk Lymphoma. 2024 Mar 5:1-4. doi: 10.1080/10428194.2024.2325188.
     PubMed    
     
     
     
271. BRAUNSTEIN Z, Waller A, Dotson E, McLaughlin E, et al
     Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
     Leuk Lymphoma. 2024;65:301-311.
     PubMed     Abstract available
     
     
     February 2024
272. MINSON A, Dickinson M
     Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.
     Leuk Lymphoma. 2024 Feb 29:1-2. doi: 10.1080/10428194.2024.2320833.
     PubMed    
     
     
     
273. WEI C, Zhai F, Jia C, Zhang W, et al
     Immunochemotherapy triggered reversible cerebral vasoconstriction syndrome in a patient with intravascular large B-cell lymphoma.
     Leuk Lymphoma. 2024 Feb 22:1-4. doi: 10.1080/10428194.2024.2316252.
     PubMed    
     
     
     
274. TASHAKORI M, Medeiros LJ
     Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasms.
     Leuk Lymphoma. 2024 Feb 21:1-5. doi: 10.1080/10428194.2024.2319691.
     PubMed     Abstract available
     
     
     
275. NEMEC R, Scherrer-Crosbie M, Abramson JS, Redd R, et al
     Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.
     Leuk Lymphoma. 2024 Feb 21:1-6. doi: 10.1080/10428194.2024.2317343.
     PubMed     Abstract available
     
     
     
276. MURPHY L, Siegele B, Carstens B, Hartman L, et al
     A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
     Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
     PubMed    
     
     
     
277. OSTERGAARD S, Schejbel L, Breinholt MF, Pedersen MO, et al
     Mutational landscape in Waldenstrom macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
     Leuk Lymphoma. 2024 Feb 10:1-10. doi: 10.1080/10428194.2024.2313623.
     PubMed     Abstract available
     
     
     
278. MAGRO CM, Kalomeris T, Shreve CR, Geyer JT, et al
     Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration.
     Leuk Lymphoma. 2024 Feb 5:1-9. doi: 10.1080/10428194.2024.2310139.
     PubMed     Abstract available
     
     
     
279. GRIEVE C, Joseph A, Drullinsky P, Zelenetz AD, et al
     Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
     Leuk Lymphoma. 2024;65:235-241.
     PubMed     Abstract available
     
     
     January 2024
280. LEI MM, Sorial MN, Lou U, Yu M, et al
     Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
     Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
     PubMed     Abstract available
     
     
     
281. ARYA S, Mozessohn L, Gong I, Faught N, et al
     The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.
     Leuk Lymphoma. 2024 Jan 24:1-9. doi: 10.1080/10428194.2024.2306463.
     PubMed     Abstract available
     
     
     
282. LIONEL AC, Gurumurthi A, Fetooh A, Eldaya R, et al
     Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
     Leuk Lymphoma. 2024 Jan 22:1-5. doi: 10.1080/10428194.2024.2304622.
     PubMed    
     
     
     
283. GRAVENMIER C, Shah B, Hussaini M, Zhang L, et al
     Chimeric antigen receptor T-cells might unmask transdifferentiated histiocytic sarcoma during diffuse large B-cell lymphoma treatment.
     Leuk Lymphoma. 2024 Jan 19:1-5. doi: 10.1080/10428194.2023.2301038.
     PubMed    
     
     
     
284. JIN Q, Jiang H, Yue N, Zhang L, et al
     The prognostic value of CD8(+) CTLs, CD163(+) TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma.
     Leuk Lymphoma. 2024 Jan 10:1-9. doi: 10.1080/10428194.2023.2296364.
     PubMed     Abstract available
     
     
     
285. LAORUANGROJ C, Atherton PJ, Wiseman GA, Ansell S, et al
     The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
     Leuk Lymphoma. 2024 Jan 8:1-6. doi: 10.1080/10428194.2023.2295792.
     PubMed     Abstract available
     
     
     
286. DICKINSON M, Martinez-Lopez J, Jousseaume E, Yang H, et al
     Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
     Leuk Lymphoma. 2024 Jan 5:1-10. doi: 10.1080/10428194.2023.2289854.
     PubMed     Abstract available
     
     
     
287. VIVIANI S, Vanazzi A, Frassoni S, Rusconi C, et al
     High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
     Leuk Lymphoma. 2024 Jan 2:1-12. doi: 10.1080/10428194.2023.2298273.
     PubMed     Abstract available
     
     
     
288. GORDON ER, Kwinta BD, Schreidah CM, Fahmy LM, et al
     Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes.
     Leuk Lymphoma. 2024;65:48-54.
     PubMed     Abstract available
     
     
     
289. RIVERA-FRANCIA VM, Failoc-Rojas VE, Villacorta-Carranza R, Leon Garrido-Lecca A, et al
     Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.
     Leuk Lymphoma. 2024;65:37-47.
     PubMed     Abstract available
     
     
     December 2023
290. HARRYSSON S, Eloranta S, Ekberg S, Enblad G, et al
     Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.
     Leuk Lymphoma. 2023 Dec 22:1-4. doi: 10.1080/10428194.2023.2296361.
     PubMed    
     
     
     
291. KANEDA Y, Kanemura N, Nakamura N, Ikoma Y, et al
     The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma.
     Leuk Lymphoma. 2023 Dec 20:1-7. doi: 10.1080/10428194.2023.2295787.
     PubMed     Abstract available
     
     
     
292. KUIPERS MT, Spanjaart AM, Bonifazi F, diBlasi R, et al
     Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
     Leuk Lymphoma. 2023 Dec 9:1-4. doi: 10.1080/10428194.2023.2288804.
     PubMed    
     
     
     
293. KAWASAKI N, Tomita M, Yamashita-Kashima Y, Yoshimura Y, et al
     Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
     Leuk Lymphoma. 2023;64:1938-1948.
     PubMed     Abstract available
     
     
     
294. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
     Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
     Leuk Lymphoma. 2023;64:2333-2337.
     PubMed    
     
     
     
295. REYNOLDS G, Anderson MA, Thursky K, Teh BW, et al
     Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis.
     Leuk Lymphoma. 2023;64:2057-2070.
     PubMed     Abstract available
     
     
     
296. PENA J, Cull D, Strowd LC, Vaidya R, et al
     Response and local control in patients treated with low-dose radiotherapy for tumoral mycosis fungoides.
     Leuk Lymphoma. 2023;64:2202-2207.
     PubMed     Abstract available
     
     
     November 2023
297. CHOHAN KL, Bansal R, Hathcock MA, Paludo J, et al
     Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
     Leuk Lymphoma. 2023 Nov 30:1-5. doi: 10.1080/10428194.2023.2285236.
     PubMed    
     
     
     
298. ZHONG Q, Liu Y, Wu Y, Liu X, et al
     Impact of age on long-term relative survival benefit of radiotherapy for early-stage grade I-II follicular lymphoma from the SEER database (2000-2015).
     Leuk Lymphoma. 2023 Nov 21:1-11. doi: 10.1080/10428194.2023.2283296.
     PubMed     Abstract available
     
     
     
299. FOUILLET L, Daguenet E, Tavernier E, Ghesquieres H, et al
     Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.
     Leuk Lymphoma. 2023 Nov 15:1-5. doi: 10.1080/10428194.2023.2281270.
     PubMed    
     
     
     
300. PACHECO JM, Forchhammer S, Otto F, Fend F, et al
     Primary cutaneous anaplastic large cell lymphoma with DUSP22-rearrangement presenting as a mimicker of mycosis fungoides: a case report and review of the literature.
     Leuk Lymphoma. 2023 Nov 7:1-5. doi: 10.1080/10428194.2023.2276678.
     PubMed    
     
     
     
301. NEWSAM AD, Coughlin CA, Trabolsi A, Schatz JH, et al
     Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma.
     Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2258244.
     PubMed     Abstract available
     
     
     
302. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
     Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
     Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
     PubMed     Abstract available
     
     
     
303. DUAN Y, Gao H, Zhou C, Jin L, et al
     Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China.
     Leuk Lymphoma. 2023 Nov 2:1-6. doi: 10.1080/10428194.2023.2263120.
     PubMed    
     
     
     October 2023
304. VILLENEUVE PJ, Harris SA
     Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma.
     Leuk Lymphoma. 2023 Oct 30:1-3. doi: 10.1080/10428194.2023.2275529.
     PubMed    
     
     
     
305. KUMAR AJ, Pearson LK, Wong JB, Friedberg JW, et al
     Understanding treatment decisions for Hodgkin lymphoma: a qualitative study.
     Leuk Lymphoma. 2023 Oct 28:1-9. doi: 10.1080/10428194.2023.2256913.
     PubMed     Abstract available
     
     
     
306. WOOTEN SV, Amini B, Roth M, Leung CH, et al
     Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
     Leuk Lymphoma. 2023 Oct 25:1-7. doi: 10.1080/10428194.2023.2273747.
     PubMed     Abstract available
     
     
     
307. ASMUSSEN A, Quintanilla-Martinez L, Larsen M, Fagerberg C, et al
     Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case.
     Leuk Lymphoma. 2023 Oct 23:1-5. doi: 10.1080/10428194.2023.2264425.
     PubMed     Abstract available
     
     
     
308. HESS G, Dreyling M, Oberic L, Gine E, et al
     Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
     Leuk Lymphoma. 2023 Oct 16:1-12. doi: 10.1080/10428194.2023.2268228.
     PubMed     Abstract available
     
     
     
309. MCGOUGH SF, Shamas N, Wang J, Jaber M, et al
     Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
     Leuk Lymphoma. 2023 Oct 15:1-10. doi: 10.1080/10428194.2023.2262066.
     PubMed     Abstract available
     
     
     
310. GRIBBIN C, Chen J, Martin P, Ruan J, et al
     Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
     Leuk Lymphoma. 2023 Oct 6:1-13. doi: 10.1080/10428194.2023.2264430.
     PubMed     Abstract available
     
     
     
311. STUVER R, Vardhana SA, Bedmutha A, Chan KK, et al
     Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.
     Leuk Lymphoma. 2023 Oct 5:1-3. doi: 10.1080/10428194.2023.2262641.
     PubMed    
     
     
     
312. IKEDA D, Oura M, Uehara A, Tabata R, et al
     Efficacy of darinaparsin for EBV-associated B-cell lymphoma in a heavily treated elderly patient with angioimmunoblastic T-cell lymphoma: a case report.
     Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2265001.
     PubMed    
     
     
     
313. ZAK T, Santana-Santos L, Gao J, Behdad A, et al
     Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma.
     Leuk Lymphoma. 2023 Oct 5:1-11. doi: 10.1080/10428194.2023.2264429.
     PubMed     Abstract available
     
     
     September 2023
314. IP A, Petrillo A, Della Pia A, Lee GG, et al
     Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
     Leuk Lymphoma. 2023 Sep 23:1-11. doi: 10.1080/10428194.2023.2259528.
     PubMed     Abstract available
     
     
     
315. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
     Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
     Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
     PubMed     Abstract available
     
     
     
316. ABDULRAHMAN N, Leo R, Boumenar HA, Ahmad F, et al
     Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
     Leuk Lymphoma. 2023 Sep 14:1-13. doi: 10.1080/10428194.2023.2256909.
     PubMed     Abstract available
     
     
     
317. FRERET ME, Tringale KR, Boe L, Imber BS, et al
     Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
     Leuk Lymphoma. 2023 Sep 14:1-7. doi: 10.1080/10428194.2023.2255706.
     PubMed     Abstract available
     
     
     
318. GORDON MJ, Duan Z, Zhao H, Nastoupil L, et al
     Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
     Leuk Lymphoma. 2023 Sep 14:1-11. doi: 10.1080/10428194.2023.2256908.
     PubMed     Abstract available
     
     
     
319. DAHI PB, Kenny S, Flynn J, Devlin SM, et al
     Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
     Leuk Lymphoma. 2023 Sep 10:1-7. doi: 10.1080/10428194.2023.2256912.
     PubMed     Abstract available
     
     
     
320. LEICH E, Brodtkorb M, Schmidt T, Altenbuchinger M, et al
     Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy.
     Leuk Lymphoma. 2023 Sep 8:1-11. doi: 10.1080/10428194.2023.2240462.
     PubMed     Abstract available
     
     
     
321. GOENKA L, Kumar SM, Essakky S, Rajasulochana SR, et al
     Cost-effectiveness of response-adapted therapy (RAT) for advanced Hodgkin's Lymphoma compared with conventional treatment in India: a Markov-model based analysis.
     Leuk Lymphoma. 2023 Sep 5:1-7. doi: 10.1080/10428194.2023.2249154.
     PubMed     Abstract available
     
     
     August 2023
322. BECERRIL-RICO J, Delgado-Montes YA, Ortiz-Sanchez E
     Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
     Leuk Lymphoma. 2023 Aug 7:1-10. doi: 10.1080/10428194.2023.2243357.
     PubMed     Abstract available
     
     
     March 2023
323. BAGGIO D, Wellard C, Chung E, Talaulikar D, et al
     Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
     Leuk Lymphoma. 2023;64:621-627.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum